Leukemia & Lymphoma最新文献

Mutational landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) involving the central nervous system. 慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）累及中枢神经系统的突变景观。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-18 DOI: 10.1080/10428194.2025.2452341

Anna Shestakova, Nahideh Haghighi, Ying Zhang, Jana Tarabay, Mark G Evans, Anton Burtsev, Jefferson Y Chan, Ashley Gamayo, Xiaohui Zhao, Susan O'Brien, Fabiola Quintero-Rivera, Sherif A Rezk

引用次数: 0

A pilot study of lower doses of ibrutinib: patient body weight does not correlate with plasma ibrutinib levels during therapy. 低剂量伊鲁替尼的初步研究：患者体重与治疗期间血浆伊鲁替尼水平无关。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-08 DOI: 10.1080/10428194.2025.2461672

Lisa S Chen, Prithviraj Bose, Wei Qiao, Yongying Jiang, Qi Wu, Nichole D Cruz, Michael J Keating, Varsha Gandhi

引用次数: 0

Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey). 评估意大利细胞治疗患者的衰弱和合并症：GITMO老年调查（GITMO老年调查）的结果。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-01-15 DOI: 10.1080/10428194.2025.2451723

Michele Malagola, Luca Castagna, Mirko Farina, Simone Pellizzeri, Eliana Degrandi, Elena Oldani, Simona Bassi, Giorgia Battipaglia, Carlo Borghero, Lucia Brunello, Alessandro Busca, Raffaella Ceretti, Patrizia Chiusolo, Michele Cimminiello, Vincenzo Federico, Camilla Frieri, Piero Galieni, Sara Galimberti, Andrea Gilioli, Annalisa Imovilli, Walter Barbieri, Chiara Nozzoli, Alessandra Picardi, Eugenia Piras, Nicola Polverelli, Lucia Prezioso, Stella Santarone, Renato Scalone, Ilaria Scortechini, Bianca Serio, Cristina Skert, Alessandro Spina, Elisabetta Terruzzi, Massimo Martino

引用次数: 0

CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges. CAR-T细胞疗法治疗复发或难治性原发性中枢神经系统淋巴瘤：最新进展和挑战

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-03 DOI: 10.1080/10428194.2025.2458214

Shuzhen Xiong, Shuni Zhang, Ningning Yue, Jiajia Cao, Chongyang Wu

引用次数: 0

Progressive eosinophilia and STAT5B mutation acquisition in AML treated with azacitidine and venetoclax. 阿扎胞苷和venetoclax治疗AML的进行性嗜酸性粒细胞增多和STAT5B突变获得。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-04 DOI: 10.1080/10428194.2025.2461667

Abigail Demers, Vincent Lok, Preston Perez, David M Swoboda

引用次数: 0

High incidence of multi-joint osteonecrosis in first year following treatment for acute lymphoblastic leukemia. 急性淋巴细胞白血病治疗后第一年多关节骨坏死的高发。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-01-15 DOI: 10.1080/10428194.2025.2452340

Alison K Heilbronner, Olivia Blumberg, Alexandra Krez, Donald J McMahon, Douglas N Mintz, Joseph M Lane, Richard S Bockman, Kyung-Hyun Park-Min, Derek Hansen, Shreya Addepalli, Gail J Roboz, Emily M Stein

引用次数: 0

Effects of SCT genetic polymorphisms on methotrexate concentrations and toxicities in Chinese children with acute lymphoblastic leukemia. SCT基因多态性对中国急性淋巴细胞白血病儿童甲氨蝶呤浓度和毒性的影响。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-01-11 DOI: 10.1080/10428194.2025.2451059

Miao Li, Dan-Qi Zhao, Xiao-Yan Kong, Shu-Mei Wang

{"title":"Effects of SCT genetic polymorphisms on methotrexate concentrations and toxicities in Chinese children with acute lymphoblastic leukemia.","authors":"Miao Li, Dan-Qi Zhao, Xiao-Yan Kong, Shu-Mei Wang","doi":"10.1080/10428194.2025.2451059","DOIUrl":"10.1080/10428194.2025.2451059","url":null,"abstract":"Solute carrier (SLC) transporters play a crucial role in facilitating the cellular uptake of various anticancer drugs, such as methotrexate (MTX). This study aimed to analyze the impact of nonsynonymous single nucleotide polymorphisms (SNPs) in SLC19A1, SLCO1B1, and SLCO1B3 on MTX exposure, toxicities, and prognosis in 148 patients with acute lymphoblastic leukemia (ALL). The SLCO1B3 rs7311358 polymorphism was significantly associated with the median dose-normalized MTX concentrations at 24 h (p < .05). There were significant differences in the proportions of patients with serum MTX levels >40 µmol/L at 24 h among SLC19A1 rs1051266 GG, GA, and AA genotype carriers (29.0, 24.7, and 6.2%, respectively, p < .05). The SLC19A1 rs1051266 G > A polymorphism also displayed significant associations with hematological (p < .05) and hepatic toxicities (p < .01). Our findings indicate that the analysis of SNPs in solute carrier transporters (SCTs) could offer valuable insights into the interpatient variability of MTX pharmacokinetics and toxicities in ALL children.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1068-1078"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clozapine is associated with an increased risk of Hodgkin and non-Hodgkin lymphoma. 氯氮平与霍奇金淋巴瘤和非霍奇金淋巴瘤的风险增加有关。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-12 DOI: 10.1080/10428194.2025.2461663

Connor Frey, Mahyar Etminan

引用次数: 0

Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network). 早期弥漫性大B细胞淋巴瘤患者的治疗方法：托斯卡纳区域淋巴瘤网络（RTL）的回顾性、多中心、现实研究

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-01-21 DOI: 10.1080/10428194.2025.2456094

Emanuele Cencini, Marianna Palazzo, Dimitri Dardanis, Giulia Lucco Navei, Lara Mannelli, Valentina Zoi, Bianca Mecacci, Benedetta Sordi, Giulia Cervetti, Serena Rosati, Luca Nassi, Monica Bocchia, Alberto Fabbri

{"title":"Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network).","authors":"Emanuele Cencini, Marianna Palazzo, Dimitri Dardanis, Giulia Lucco Navei, Lara Mannelli, Valentina Zoi, Bianca Mecacci, Benedetta Sordi, Giulia Cervetti, Serena Rosati, Luca Nassi, Monica Bocchia, Alberto Fabbri","doi":"10.1080/10428194.2025.2456094","DOIUrl":"10.1080/10428194.2025.2456094","url":null,"abstract":"Treatment strategies for early stage diffuse large B-cell lymphoma (ES-DLBCL) include R-CHOP, with a similar schedule to that used in advanced stage, or a reduced number of cycles followed by radiation therapy (RT). We retrospectively analyzed 179 ES-DLBCL patients, managed according to the clinical practice. Treatment regimens include chemoimmunotherapy 4-6 cycles +/- RT as consolidation. First-line therapy was R-CHOP/CHOP-like in 88.8% of cases. RT as consolidation was administered to 29.9% of cases. Complete response rate was 87.2%, median PFS and OS were not reached. IPI 2-3 and first-line regimen with 3-4 cycles of R-CHOP without RT were the 2 prognostic variables for OS in multivariate analysis. After a median follow-up of 48 months, 31 patients died (17.3%). We suggest that both R-CHOP 6 cycles and 3-4 cycles followed by RT as consolidation seem to be valid first-line regimens, while an abbreviated strategy without RT could be associated to inferior outcome.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1111-1120"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas. 阿仑单抗和剂量调整EPOCH-R治疗复发或难治性侵袭性b细胞淋巴瘤的2期研究

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-03 DOI: 10.1080/10428194.2025.2457553

Rahul Lakhotia, Christopher Melani, Kieron Dunleavy, Stefania Pittaluga, Sanjal Desai, Mark A Ahlman, Nicole Lucas, Seth M Steinberg, Elaine S Jaffe, Wyndham H Wilson, Mark Roschewski

{"title":"Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.","authors":"Rahul Lakhotia, Christopher Melani, Kieron Dunleavy, Stefania Pittaluga, Sanjal Desai, Mark A Ahlman, Nicole Lucas, Seth M Steinberg, Elaine S Jaffe, Wyndham H Wilson, Mark Roschewski","doi":"10.1080/10428194.2025.2457553","DOIUrl":"10.1080/10428194.2025.2457553","url":null,"abstract":"Immune cells within the lymphoma tumor microenvironment promote immune evasion and are rational therapeutic targets. Alemtuzumab targets CD52 expressed on malignant B-cells and infiltrating nonmalignant T-cells. We evaluated the safety and efficacy of alemtuzumab with DA-EPOCH-R in 48 patients with relapsed/refractory aggressive B-cell lymphoma. Febrile neutropenia occurred in 18% of cycles and serious infections in 21% of patients. Responses were observed in 30 (62%) patients, including 12 (80%) patients with classical HL and 3 (75%) patients with T-cell/histiocyte-rich large B-cell lymphoma (THRLCL). Seventeen (35%) patients achieved complete responses, and 12 (25%) were bridged to consolidation. The 2-year progression-free survival (PFS) and overall survival were 22.1% (95% CI, 11.5-34.7%) and 45.2% (95% CI, 34.3-58.9%), respectively. The 2-year PFS for HL and THRLCL patients was 35% and 50%, respectively. Alemtuzumab can be safely combined with DA-EPOCH-R in relapsed/refractory aggressive B-cell lymphomas and can induce durable responses in patients with T-cell-rich microenvironments.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1088-1099"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0